Successful treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine.
End-stage renal failure and long-term hemodialysis treatment promote the development of genetically conditioned porphyria cutanea tarda (PCT). The clinical manifestation is triggered off by unknown factors coexisting with renal insufficiency and hemodialysis. Iron overload is often associated with the disease and is thought to play a key role in its pathogenesis. Iron removal by deferoxamine infusions is regarded as the treatment of choice for patients who cannot undergo repeated phlebotomy procedures and has been successfully used in patients with normal renal function. We report a case of hemodialysis-related PCT and iron overload in whom repeated venesections were contraindicated on account of severe anemia and treatment with deferoxamine led to a striking improvement of symptoms.
Stockenhuber
F
F
Department of Renal Disease and Hemodialysis, Vienna University School of Medicine, Austria.
Kurz
R
R
Grimm
G
G
Moser
G
G
Balcke
P
P
D003676:Deferoxamine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011164:Porphyrias / Q000188:drug therapy* / Q000209:etiology; D006435:Renal Dialysis / Q000009:adverse effects*; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology
D003676:Deferoxamine